IDO1 and head and neck squamous cell carcinoma: Additionally, a phase II trial of nivolumab (anti-PD-1) and an oral IDO-1 inhibitor BMS986205 (NCT03854032) is currently underway for the treatment of patients with stage II-IV HNSCC [48].